Question of The Week -- October 29, 2020

As outlined this past week by The Boston Globe, executives and board members at pharmaceutical companies involved in the development of Covid-19 vaccines have been amassing small fortunes during the past few months through the sale of stock they own in those companies -- benefiting from public speculation on the efficacy of such vaccines. Although legally, on its face, there is nothing wrong with such sales, is it time for the SEC to take a closer look at placing restrictions on stock sales by insiders at pharmaceutical companies?